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PC7 belongs to the proprotein convertase family, whose members
are implicated in the cleavage of secretory precursors. The in vivo
function of PC7 is unknown. Herein, we ﬁnd that the precursor
proBDNF is processed into mature BDNF in COS-1 cells coexpressing
proBDNF with either PC7 or Furin. Conversely, the processing of
proBDNF into BDNF is markedly reduced in the absence of either
Furin or PC7 in mouse primary hepatocytes. In vivo we observe that
BDNF and PC7 mRNAs are colocalized in mouse hippocampus and
amygdala and that mature BDNF protein levels are reduced in these
brain areas in PC7 KO mice but not in the hippocampus of PC1/3 KO
mice. Various behavioral tests reveal that in PC7 KO mice spatial
memory is intact and plasticity of responding is mildly abnormal.
Episodic and emotional memories are severely impaired, but both
are rescued with the tyrosine receptor kinase B agonist 7,8-dihy-
droxyﬂavone. Altogether, these results support an in vivo role for
PC7 in the regulation of certain types of cognitive performance, in
part via proBDNF processing. Because polymorphic variants of hu-
man PC7 are being characterized, it will be important in future
studies to determine their effects on additional physiological and
behavioral processes.
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Nine secretory proprotein convertases (PCs) play major rolesin regulating multiple cellular and extracellular processes
both in health and disease states (reviewed in refs. 1 and 2). The
convertases PC1/3, PC2, Furin, PC4, PC5/6, PACE4, and PC7
cleave their substrates after single or pairs of basic amino acids,
SKI-1/S1P processes protein precursors after nonbasic residues,
and PCSK9 has no known substrates other than itself (1). Studies
that have analyzed tissue expression, levels, regulation, ontogeny,
phenotypes of model animals lacking one or more PCs, and hu-
man/mouse natural mutations are starting to provide clues as to the
speciﬁc roles of these enzymes in cells and whole-animal physio-
logical and pathological processes.
The type I membrane-bound PC7 is the most ancient member
of the mammalian basic amino acid-speciﬁc PC family, and it
exhibits the closest homology to yeast kexin (3). Human PC7 is
synthesized as anN-glycosylated zymogen (proPC7) that, like most
other PCs, undergoes autocatalytic cleavage in the endoplasmic
reticulum at RAKR141↓SV. Mature PC7 can reach the cell surface
by an unconventional route from the endoplasmic reticulum (4),
but it also accumulates in the trans Golgi network (TGN) and can
cycle between the cell surface and TGN via endosomes, in part by
virtue of a Pro-Leu-Cys726 motif in its cytosolic tail (5). The tail
also contains two cysteine residues, Cys699 and Cys704, which are
palmitoylated (3, 4, 6), that may assist in this process. Confocal
and electron microscopy studies have revealed that PC7 localizes
to vesicles located immediately beneath the plasma membrane (4,
7). No soluble shed forms of PC7 have been detected. Enzymatic
activity assays using only the soluble luminal/extracellular domain
of PC7 (sol.PC7) and ﬂuorogenic substrates have indicated that
this Ca2+-dependent enzyme exhibits a neutral pH optimum and
a cleavage speciﬁcity similar to that of Furin, cleaving within the
general motif (R/K)-2Xn-R↓ where n = 0–2 (8, 9).
Only the membrane-bound PC7 induces the processing of pro-
epidermal growth factor into a ∼115-kDa transmembrane form
(10). PC7 is abundant in neurons (11) but is also expressed in
microglia (12). It has been shown that PC7 exerts an important
function in MHC class I-mediated antigen presentation (7), beﬁt-
ting its high expression within the immune system (3). Finally, PC7
is unique because it is able to shed the human transferrin receptor
1 (TfR1) into a soluble form by cleavage at KTECER100↓LA
within endosomes (13).
The physiological importance of the PCs is illustrated by the
early death or major phenotypes observed in mice lacking one or
more convertase (1, 14). Although generated several years ago,
deletion of PC7 is the only PC KO mouse for which no overt
phenotype(s) has been described (15). In contrast, PC7 knockdown
in Xenopus is embryonic lethal. These embryos lack eyes and brain
and exhibit abnormal anterior neural development (16). Unless
Signiﬁcance
The 7-membered proprotein convertase (PC) family of basic
amino acid-speciﬁc proteases is implicated in the cleavage-
activation of secretory precursor proteins. Although the in vivo
functions of most members have been well studied, those of
the seventh member PC7 are largely unknown. Herein, we ﬁnd
that PC7 participates in the generation of mature BDNF both in
cells and in speciﬁc brain areas such as hippocampus and
amygdala. Indeed, PC7 exerts a critical role in the brain: The
results of various behavioral tests in normal mice compared
with those lacking PC7 expression support an in vivo role for
PC7 in the regulation of certain types of cognitive performance,
such as emotional memories, in part via BDNF activation.
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this knockdown is due to an off-target effect, amphibian PC7
seems to fulﬁll essential neuronal functions that, in mammals,
may be either nonessential or redundantly assumed by other
PCs. Notably, the regulation of the PC7 gene (PCSK7) has not
been examined (3, 17).
In the present work we describe behavioral alterations in mice
lacking PC7. Our results show that PC7 KOmice have lower levels
of BDNF in the hippocampus and amygdala than WT mice and
exhibit learning and memory impairments. Reduced BDNF levels
are likely responsible for some of these deﬁcits, because they are
rescued by an agonist to the BDNF receptor tyrosine receptor
kinase B (TrkB). Therefore, PC7 seems to play unique roles in the
CNS, at least in part, through regulating levels of BDNF.
Results
BDNF Levels Are Reduced in PC7 KO Mice. In a recent publication
(18), we found that PC7 KO mice display anxiolytic-like behav-
ior. Because PC7 is expressed in the hippocampus and amygdala
(Fig. 1 and Fig. S1), and because these brain structures are in-
volved in anxiety responses (19), it may be the case that PC7
plays some functional role in these areas. Although a number of
peptides are present in these brain regions, transgenic BDNF
overexpression in the hippocampus and amygdala leads to in-
creased anxiogenesis in mice (20). These relationships prompted
us to examine the status of BDNF in PC7 mice.
In situ hybridization revealed that PC7 and BDNF mRNAs
were colocalized in hippocampus and amygdala (Fig. 1). Using
quantitative PCR (Table S1), we determined that the levels of
BDNF mRNA in both brain areas were similar between PC7 KO
and WT mice (Table S2). Western blot analyses from brain tissue
extracts revealed that the levels of mature BDNF protein were
signiﬁcantly (∼40%) lower in PC7 KO than in WT hippocampus
(P < 0.05) and amygdala (P < 0.01) (Fig. 2). In agreement with a
previous report showing that the precursor proBDNF is present
in very small quantities in brain (21), a longer exposure of the
Western blot ﬁlm revealed that proBDNF levels did not signiﬁ-
cantly vary between the WT and KO mice (Fig. 2). This differ-
ence between proBDNF and mature BDNF levels suggested that
the precursor may be selectively destabilized in PC7 KO tissues.
Mature Sortilin has been reported to participate in the stabili-
zation of proBDNF and to protect it from degradation (22).
Sortilin is a type-1 membrane-bound receptor expressed in the
central and peripheral nervous systems, which is synthesized as
a precursor (proSortilin) that is converted to the mature receptor
in vitro at the conserved RWRR77↓SA site by Furin (23). Be-
cause this motif does not exclude the participation of other PCs,
we tested whether proSortilin could also be a substrate for PC7.
Indeed, in HEK293 cells cotransfection of a cDNA coding for
proSortilin with cDNAs for either Furin or PC7 revealed that
both convertases can completely process proSortilin and likely
activate Sortilin (Fig. S2A). Hence, when PC7 is absent, pro-
Sortilin would not be processed sufﬁciently such that lower levels
of proBDNF would be detected. This effect may explain why
proBDNF levels were similar between WT and PC7 KO mice de-
spite the ∼40% decrease of BDNF in the PC7 KO mice (Fig. 2).
Our data suggest that proBDNF processing is reduced in PC7
KO mice. Because the enzymatic conditions and cleavage spe-
ciﬁcities are similar for Furin and PC7 (8, 9), we overexpressed
human proBDNF in primary hepatocytes isolated from livers of
Furin KO or PC7 KO mice. We observed reductions in secretion
of mature BDNF by ∼65% and ∼35% in absence of Furin and
PC7, respectively (Fig. S2B). Besides these two convertases,
PC1/3 has been reported to process proBDNF in vitro (24).
However, in our hands the levels of hippocampal BDNF in WT
and PC1/3 KO mice were indistinguishable (Fig. S2C).
To examine the roles of Furin and PC7 in processing proBDNF
in greater detail, we used an in vitro system. In COS-1 cells
coexpressing proBDNF and PC7, we found that PC7, like Furin,
induced an increase in mature BDNF levels in cell extracts and
media (Fig. S2D). However, mostly membrane-bound PC7 was
active in processing proBDNF, compared with Furin, whereas
soluble Furin (sol.Furin) generated more secreted BDNF than
its membrane-bound form. This requirement for full-length PC7
was also observed for the shedding of human TfR1 (13), sug-
gesting here also that proBDNF cleavage by PC7 occurs at the
cell surface and/or in endosomes. Importantly, mRNA levels of
other PC family members (24) or members of the tissue plas-
minogen activator (tPA)/plasmin pathway (25) were not down-
regulated in the hippocampus and amygdala of the two geno-
types (Table S2), demonstrating that they are not responsible for
the decrease in BDNF protein levels in these brain areas of PC7
KO mice.
PC7 KO Mice Are Deﬁcient in Episodic Memory and a TrkB Agonist
Rescues the Response. Because PC7 KO mice do not exhibit vis-
ible abnormalities (15) and because PC7 is expressed in the
hippocampus (Fig. 1), we examined cognition. WT and PC7 KO
mice were indistinguishable on tests of gross sensory and motor
performance (Table S3). Episodic memory, recollection of past
events or experiences, was examined with the social transmission
of food preference (STFP) and the novel object recognition
memory (NORM) tests (26). To monitor STFP, a demonstrator
mouse that ate a ﬂavored diet was returned to its home cage to
interact with its cage-mates. The cage-mates were tested 20 min
later (short-term memory, STM) and 24 h later (long-term mem-
ory, LTM) for their preference between the demonstrator and
a novel-ﬂavored diet. This choice depends on the ability of tester
mice to detect and remember olfactory cues on the breath and
whiskers of the demonstrator during their social interaction in the
home-cage. A score of zero means no preference for either diet,
whereas a positive score reﬂects a preference for the demonstrator
diet. WT control mice strongly preferred the demonstrator diet at
both time points, whereas this preference was signiﬁcantly de-
creased in the PC7 KO animals (Fig. 3A, Left). Importantly, these
reduced preferences were not due to alterations in social inter-
actions between the demonstrator and tester mice (nose-to-nose
contacts per tester-mouse, WT: 136 ± 11, PC7 KO: 151 ± 9; du-
ration of contacts, WT: 46 ± 6, PC7 KO: 62 ± 8 s per tester-
mouse), the amount of food eaten, time spent with the diets,
bowl contacts, or latency to ﬁrst bowl contact (Fig. S3 A–D).
Fig. 1. Comparative distributions of BDNF and PC7 mRNA. Three adjacent
sections of an adult mouse brain at the level of the basolateral (BL)
amygdaloid nucleus were submitted to (A) PC7 and (B) BDNF in situ hybrid-
ization (dark-ﬁeld illumination). Cx, cerebral cortex; DG, dentate gyrus; Hi,
hippocampus; VMH, ventromedial hypothalamic nucleus. Emulsion autoradi-
ography of (C) PC7 and (D) BDNF expression in pyramidal neurons (arrows) of
the BL amygdaloid nucleus, followed by staining with cresyl violet.
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On day 1 of NORM testing, mice were presented with two
identical objects. Twenty minutes (STM) and 24 h (LTM) later
mice were presented with the now familiar and a novel object (27).
If mice spend more time examining the novel object, it signiﬁes
that they recognize and remember the familiar one. Preference for
the novel object in the two memory tests was signiﬁcantly lower for
PC7 KO than for WT mice (Fig. 3A, Right). This reduced pref-
erence for the novel object was not related to the number of object
contacts or the latency to the ﬁrst object contact (Fig. S3 E and F).
Because LTM in this test was especially impaired and because
BDNF levels were reduced in the PC7 KO mice, we injected (i.p.)
another cohort of mice 1 h before training with 0.7 mg/kg 7,8-
dihydroxyﬂavone (DHF), a brain-penetrable BDNF receptor
(TrkB) agonist (28, 29). When tested 24 h after training, per-
formance of the PC7 KO mice was virtually identical to that of
the WT controls (Fig. 3A, Right). Together, the results from the
episodic memory tests indicate that hippocampal function is
abnormal in PC7 KOmice and that DHF can rescue the response.
Mice were next evaluated in the Morris water maze (27). Swim
times in the visible platform test were similar in WT and PC7 KO
mice (Fig. S4A), demonstrating that motor performance, visual
abilities, and motivation were similar between genotypes. In
acquisition testing with the hidden platform, swim times (Fig. 3B,
Left) and swim distances (Fig. S4 B and C) were similar between
genotypes. However, when the location of the platform was
moved from one quadrant to another, swim time and swim dis-
tance were initially prolonged for the PC7 KO mice (Fig. 3B,
Right). The probe trial results conﬁrmed these ﬁndings (Fig. S4 D
and E). These data indicate that although spatial memory
appears intact, plasticity of responding is mildly deﬁcient in PC7
KO mice.
PC7 KO Mice Are Impaired in Emotional Memory, and a TrkB Agonist
Rescues the Response. Emotional learning and memory processes
were examined by fear conditioning and fear-potentiated startle
(FPS) (27). In fear conditioning, responses are measured by
freezing, which can be elicited by associating a neutral cue (e.g.,
environmental context or tone) with an aversive event (e.g.,
electric foot-shock) (30, 31). Because tissue levels of BDNF were
reduced in PC7 KO mice, we conducted these tests with animals
injected (i.p.) with saline (vehicle) or DHF and conditioned the
mice 1 h later. When the vehicle-treated mice were evaluated 1 h
(STM) or 24 h (LTM) after conditioning, we found that freezing
was enhanced in the context test at both time points in WT mice,
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Fig. 2. The hippocampus and amygdala of PC7 KO mice contain lower levels of mature BDNF protein. (A) Schematic representation of the BDNF precursor
and its PC cleavage site (arrow). Representative Western blot analysis of protein extracts from the (B) hippocampus and (C) amygdala of WT and PC7 KO mice,
using a BDNF-speciﬁc antibody. The preabsorption control (left lane) demonstrates the speciﬁcity of the antibody. Normalized relative band intensities with
respect to β-actin revealed a signiﬁcant decrease in mature BDNF levels in both tissues (n = 11 mice/brain area/genotype); Student t test probability: *P < 0.05;
**P < 0.01.
Fig. 3. PC7 KO mice are deﬁcient in episodic memory. (A) Preference scores
in the STFP and NORM tests for STM and LTM. n = 11 mice/genotype; *P <
0.05, WT vs. PC7 KO mice. (B) Time to locate the hidden platform in the
Morris water maze. n = 10 mice/genotype; *P < 0.05, WT vs. PC7 KO mice;
@P < 0.05, within genotype CTL vs. DHF at the 24 h test time.
17364 | www.pnas.org/cgi/doi/10.1073/pnas.1314698110 Wetsel et al.
whereas freezing was reduced in PC7 KO animals (Fig. 4A, Left
and Center). In the cued test before presentation of the condi-
tioned stimulus (CS), freezing was very low in both genotypes
(Fig. 4B, Left and Center). However, we observed that freezing to
the CS was increased at 1 h and 24 h in the WT vehicle-controls,
whereas freezing in PC7 KO animals was not different between
the pre-CS and CS intervals at either time point. We tested the
DHF-treated mice 24 h after conditioning, when responses were
most robust. We found that DHF enhanced freezing in the PC7
KO mice in both the contextual and cued tests to levels that were
similar to those of the WT controls (Fig. 4 A and B, Center and
Right). Importantly, sensitivity to foot-shock was not distin-
guished by genotype or treatment condition (Fig. S5 A and B).
Hence, PC7 KO mice are impaired in both STM and LTM in
contextual and cued fear conditioning, and these responses are
rescued by the TrkB agonist.
Because deﬁciencies in contextual and cued fear conditioning
indicate amygdala dysfunction (30, 32), mice were evaluated in
FPS, an amygdala test (27). On day 1, baseline startle responses
were higher in PC7 KO mice than in WT animals (Fig. S5C). On
day 2, no genotypic differences in startle potentiation were ob-
served to these same acoustic stimuli (Fig. S5D). On the next
day, mice were injected with vehicle or 0.7 mg/kg DHF (i.p.) and
conditioned 1 h later. When FPS was examined 48 h later in
vehicle-treated mice, we observed that the 0.2-mA shock was
without effect in either genotype (Fig. 4C, Left). Despite this
fact, only vehicle-treated WT mice showed FPS after condi-
tioning to the 0.4- or 0.6-mA shock (Fig. 4C, Center). Because 0.4
mA was a moderate level of shock in this test (27), we evaluated
the effects of DHF at this intensity. We found that the levels of
FPS in DHF-treated PC7 KO mice were indistinguishable from
those of the WT mice given the vehicle or DHF (Fig. 4C, Center
Left and Right). Collectively, these ﬁndings indicate that PC7 KO
mice are deﬁcient in fear memories and that a TrkB agonist can
normalize these responses in the mutant mice.
Discussion
In the present investigation we report that BDNF and PC7 are
colocalized in mouse hippocampus and amygdala and that PC7
KO mice have ∼40% reduced levels of mature BDNF protein in
these same brain areas, with no effect on BDNF mRNA. Ad-
ditionally, we demonstrate that when proBDNF and PC7 are
coexpressed in COS-1 cells, this precursor is processed by PC7
into mature BDNF and that the levels of secreted BDNF from
primary hepatocytes lacking PC7 are reduced by ∼35%. Behav-
iorally, we ﬁnd that spatial memory is intact in PC7 KO mice,
whereas plasticity of responding is mildly abnormal. Both epi-
sodic and emotional memories are impaired in these mutants,
but they are rescued with the TrkB agonist DHF. Collectively
these ﬁndings indicate that PC7 is a proBDNF processing en-
zyme in vivo and that deletion of PC7 in mice is deleterious to
certain types of cognitive performance.
Although we examined many potential substrates for PC7
(10), we ﬁnally focused on BDNF because of our behavioral
results. BDNF is known to regulate neuronal development, dif-
ferentiation, and survival of neurons and to mediate synaptic
plasticity (33). Because proBDNF can be processed intracel-
lularly by several PC family members (24) and extracellularly by
the tPA/plasmin cascade (25) and because PC7 was cloned after
these studies were published (3), proBDNF processing by PC7
was not tested in our original report (24). PC7 is expressed in
many tissues, including the hippocampus and amygdala, which
are known to synthesize BDNF (3). We ﬁnd that PC7 can pro-
cess proBDNF into its mature form and that its absence from
primary hepatocytes reduces proBDNF processing. These ﬁnd-
ings agree with our in vivo observations, which demonstrate that
BDNF levels are lower in the PC7 KO than in WT hippocampus
and amygdala. Together these results suggest that decreased
BDNF levels in PC7 KO mice are directly related to reduced
proBDNF processing. Interestingly, whereas mature BDNF levels
were signiﬁcantly reduced in PC7 KOmice, those of the proBDNF
were not. One possible explanation for these ﬁndings is that PC7
affects proBDNF via two separate mechanisms. Processing of
proSortilin would be reduced in PC7 KO mice, and this should
increase degradation of proBDNF (22). By contrast, decreased
processing of proBDNF may be expected to increase its levels.
The net effect would be no change in proBDNF in PC7 KO
mice, and these concentrations would be indistinguishable from
the WT control. We also noted that the lack of PC1/3 does not
signiﬁcantly affect BDNF levels in the hippocampus. Furthermore,
the mRNA levels of other proteases implicated in proBDNF
processing (i.e., certain PC family members and the tPA/plasmin
cascade) are not down-regulated in PC7 KO mice. Hence, it does
not seem that these other proteases undergo compensatory regu-
lation in the PC7 KO hippocampus and amygdala.
Alterations in BDNF levels in vivo can affect cognitive per-
formance. For instance, virally induced BDNF deletion in the
hippocampus disrupts NORM performance (34). Similarly, we
ﬁnd that PC7 KO mice are impaired not only in NORM but also
in STFP, another test of episodic memory. However, hippo-
campal function is not completely lost, because Morris water
maze performance is normal. Nevertheless, PC7 KO mice are
mildly deﬁcient in response plasticity on this test, suggestive of
some hippocampal abnormalities. Other investigators have noted
that water maze performance is perturbed in forebrain-deleted
BDNF mice (35) and in mice with hippocampal virally induced
BDNF ablation (34), whereas transgenic overexpression of BDNF
in the cerebral cortex and hippocampus facilitates perfor-
mance (36). The basis for the discrepancy between these and our
Fig. 4. PC7 KO mice are deﬁcient in fear memories. (A) Percent time spent
freezing in contextual fear conditioning at 1 h, or at 24 h after treatment
(i.p.) with vehicle (CTL) or 0.7 mg/kg DHF. n = 9–10 mice/genotype/condition;
*P < 0.05, WT vs. PC7 KO mice; @P < 0.05, within genotype CTL vs. DHF at the
24 h test time. (B) Percent time spent freezing in cued fear conditioning at
1 h, or at 24 h after CTL or DHF treatment. n = 9–10 mice/genotype/condition;
*P < 0.05, WT vs. PC7 KO mice; +P < 0.05, pre-CS vs. CS phase within each
test; @P < 0.05, within genotype CTL vs. DHF during the CS phase at 24 h. (C)
FPS in PC7 mice. n = 8–11 mice/genotype/treatment; *P < 0.05, WT vs. PC7
KO mice; +P < 0.05, compared with the 100-dB response within each CTL
group; P^ < 0.05, the 0.2-mA vs. the 0.4- and 0.6-mA responses within the CTL
groups; #P < 0.05, the 0.4-mA vs. the 0.6-mA response; @P < 0.05, CTL vs. DHF
in the 0.4-mA shock condition.
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results is unclear, but it may be related to differing genetic
backgrounds and brain areas affected, different behavioral pro-
tocols, and/or activities of other PC7 substrates not yet identiﬁed
in the various brain regions that subserve spatial memories (37,
38). Regardless, our data indicate that PC7 KO mice have some
hippocampal dysfunction and that hippocampal–cortical circuits
may be abnormal (39).
Emotional memory is also modulated by BDNF. For example,
fear conditioning selectively increases BDNF mRNA in the
amygdala, whereas mRNAs of other neurotrophins and trophic
factors are unaffected (40). BDNF protein levels and TrkB
phosphorylation are also enhanced by fear conditioning (41, 42).
In our studies, the concentrations of BDNF protein are reduced
in the PC7 KO hippocampus and amygdala. Moreover, these
mutants are impaired not only in contextual and cued fear
conditioning but also in FPS. Other investigators have reported
that BDNF+/−, BDNFMet/Met, and forebrain-inducible BDNF-
deleted mice are impaired in contextual fear conditioning,
whereas cued conditioning is retained (35, 43–45). Cued fear
conditioning, however, can be deﬁcient in older BDNF+/− ani-
mals (46). By contrast, transgenic overexpression of TrkB in
cortical and hippocampal subﬁelds augments contextual fear
conditioning and taste aversion (36); the latter is a test of amyg-
dala function. Our results in fear conditioning are fully compatible
with these ﬁndings, because together with our FPS results they
indicate that emotional memories are impaired in the PC7 KO
hippocampus and amygdala. It is noteworthy that these effects
cannot be attributed to the acquisition of fear conditioning, be-
cause the sensitivities to foot-shock and the freezing responses
during the pretone (WT: 7 ± 0.9 s; KO: 8 ± 1.0 s) and posttone
(WT: 23 ± 2.3 s; KO: 23 ± 2.5 s) conditioning intervals were not
different between genotypes.
Several different approaches have been taken to rescue cogni-
tive performance in BDNF-deﬁcient mice. For instance, infusion
of BDNF protein into BDNF+/− hippocampus can partially nor-
malize fear responses (43). Interestingly, more complete rescue is
achieved with DHF (47). This TrkB agonist is also reported to
enhance acquisition and prolong extinction of fear conditioning
in C57BL/6 mice (29) and to reverse some of the Alzheimer’s
disease-associated memory loss (48). It should, however, be em-
phasized that our DHF results are based on a single pharmaco-
logical approach, and that although DHF is efﬁcacious in activating
TrkB in cells (29), the speciﬁcity of this compound in vivo has
not been fully established. Despite this possible limitation in our
own studies, we ﬁnd that DHF is efﬁcacious in rescuing not only
episodic LTM but also fear LTM in PC7 KO mice. The ability to
rescue these differential memories provides additional support
that PC7 is a proBDNF processing enzyme in vivo and that its
disruption in mice has untoward behavioral consequences.
Because analysis of polymorphic variants of the human PCSK7
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?geneId=
9159) have revealed that some of the variants have func-
tional consequences [e.g., in iron metabolism (13)], it will be
important in future studies to determine not only the effects of
these mutations on proBDNF processing but also to ascertain
their possible functional effects on other physiological and
behavioral processes.
Materials and Methods
In Situ Hybridization. Ten-micrometer-thick cryosections were prepared from
brains of 3-mo-old mice, ﬁxed in 4% formaldehyde, and hybridized as pre-
viously described (49) with mouse sense (negative control) and antisense
cRNA probes. The latter probes corresponded to the mouse PC7 or mouse
BDNF coding regions for residues 1–213 or residues 25–117, respectively, and
were synthesized using 35S-UTP (PerkinElmer).
Cell Culture and cDNA Transfections. COS-1 and HEK293 cells were grown in
DMEM with 10% FBS (Invitrogen) and were maintained at 37 °C under 5%
CO2. Using Lipofectamine (Invitrogen), 80–90% conﬂuent COS-1 cells were
cotransfected with pcDNA3 recombinants of human proBDNF with a C-terminal
V5 tag together with either full-length or soluble human Furin (Furin,
sol.Furin), full-length or soluble rat PC7 (PC7, sol.PC7), or an empty pIRES
plasmid. Using jetPRIME (Polyplus), 80–90% conﬂuent HEK293 cells were
cotransfected with pcDNA3 recombinants of human proSortilin with a
C-terminal c-Myc tag together with either full-length human Furin, rat PC7,
or an empty pIRES plasmid. Twenty-four hours after transfection, the cells
were washed and incubated in serum-free medium for an additional 20 h
before medium collection and cell lysis.
Behavioral Tests. The procedures for the neurophysiological screen, STFP,
NORM, Morris water maze, fear conditioning, and FPS have been described
previously (26, 27). In pharmacology studies, mice were injected (i.p.) with
saline or DHF (29) 1 h before behavioral testing.
Additionalmaterials andmethods can be found in SI Materials andMethods.
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